Company Profile

4D pharma plc is a United Kingdom-based pharmaceutical company. The Company is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed Börse Stuttgart 04:35:41 2022-06-24 EDT			5-day change	1st Jan Change
1.450 ^EUR	-1.36%		-.--%	-

23-02-15	4D Pharma shares cancelled from trading on London's AIM	AN
23-02-15	4D pharma Cancels Trading on London's AIM	MT

23-02-15	4D Pharma shares cancelled from trading on London's AIM	AN
23-02-15	4D pharma Cancels Trading on London's AIM	MT
23-02-03	TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil	AN
23-02-02	4D pharma plc Updates Results from Renal Cell Carcinoma Cohort	CI
23-01-09	UK shareholder meetings calendar - next 7 days	AN
22-12-30	4D Pharma seeks approval for equity fundraise to lift suspension	AN
22-11-18	4D pharma's Blautix Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics	CI
22-11-16	4D Pharma says trial results show Blautix eases IBS symptoms	AN
22-09-29	4D pharma Remains Suspended from Trading on London's AIM	MT
22-09-29	4D Pharma plc Announces Delay in Publication of Interim Results for the Six Months to 30 June 2022	CI
22-08-24	4D pharma plc Announces Publication of Preclinical Research Showing Live Biotherapeutic MRx0006 Efficacy in Animal Model of Autism Spectrum Disorder	CI
22-07-06	4D pharma plc(NasdaqGM:LBPS) dropped from NASDAQ Composite Index	CI
22-07-05	4D Pharma plc Is Temporarily Pausing Recruitment into Ongoing Clinical Trials	CI

22-06-27	Chardan Capital Downgrades 4D pharma to Neutral from Buy on Likelihood of Share Dilution	MT
22-06-27	Chardan Capital Downgrades 4D pharma to Neutral from Buy	MT
22-06-27	Ladenburg Thalmann Downgrades 4D Pharma to Neutral From Buy	MT
22-03-24	Ladenburg Thalmann Adjusts Price Target on 4D Pharma to $37 From $35, Reiterates Buy Rating	MT
21-05-13	4D pharma : Ladenburg Thalmann Starts 4D Pharma at Buy With $35 Price Target	MT

22-11-15	4D pharma : Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022) - Form 6-K	PU
22-11-10	4D pharma : Presents at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)	PU
22-10-07	4D pharma : Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022) - Form 6-K	PU
22-10-05	4D pharma : Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)	PU
22-08-24	4D pharma : Publication of Joint Administrators’ Proposals - Form 6-K	PU

4D PHAR Stock Börse Stuttgart

Stocks

4DY0

US35085K1097

Biotechnology & Medical Research

Latest news: 4D PHAR

Analysts' recommendations: 4D PHAR

Press Releases: 4D PHAR

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
4D PHAR	-1.36%	-.--%	-	-	37.92M
WUXI APPTEC CO., LTD.	-1.38%	+2.23%	+48.54%	+100.96%	70.24B
ARGENX SE	-1.04%	-0.81%	+34.61%	+75.16%	62.63B
INSMED INCORPORATED	-4.10%	-4.10%	-16.33%	+350.09%	27.36B
WUXI BIOLOGICS (CAYMAN) INC.	+0.16%	+1.53%	+34.92%	+17.47%	25.71B
BIONTECH SE	-1.99%	-1.97%	-1.19%	-14.45%	24.83B
GENMAB A/S	+1.61%	-0.69%	+20.85%	-19.42%	19.52B
PHARMAESSENTIA CORPORATION	+1.26%	-9.06%	+165.21%	+308.08%	15.51B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.91%	-5.71%	-8.71%	+521.92%	14.66B
SUMMIT THERAPEUTICS INC.	-4.72%	+1.04%	-7.81%	+833.69%	14.69B
Average	-1.56%	-1.33%	+30.01%	+241.50%	30.57B
Weighted average by Cap.	-1.43%	-0.64%	+31.71%	+166.34%